Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by genetic and clinical heterogeneity and high mortality. Despite the recent introduction of novel pharmaceutical agents in hemato-oncology, few advancements have been made in AML for decades. In the last years, the the...

Full description

Bibliographic Details
Main Authors:	Michele Gottardi, Giorgia Simonetti, Alessandra Sperotto, Davide Nappi, Andrea Ghelli Luserna di Rorà, Antonella Padella, Marianna Norata, Maria Benedetta Giannini, Gerardo Musuraca, Francesco Lanza, Claudio Cerchione, Giovanni Martinelli
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Cancers
Subjects:	CD33 acute myeloid leukemia gemtuzumab ozogamicin biomarkers
Online Access:	https://www.mdpi.com/2072-6694/13/18/4566

Similar Items

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials
by: Gleissner, Beate, et al.
Published: (2014)

Gemtuzumab Ozogamicina: uma opção no tratamento de Leucemia mielóide aguda CD33+ Gemtuzumab Ozogamicin: an option in the treatment of acute myeloid leukemia CD33+
by: Celso M. Massumoto, et al.
Published: (2004-12-01)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
by: Hien K Duong, et al.
Published: (2009-05-01)

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
by: Egan PC, et al.
Published: (2018-11-01)

LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY
by: Xavier Thomas, et al.
Published: (2020-04-01)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
by: Laurène Fenwarth, et al.
Published: (2020-08-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
by: Mareque M, et al.
Published: (2021-04-01)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
by: Michele Gottardi, et al.
Published: (2017-09-01)

Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports)
by: DV Zaitsev, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
by: Mareque M, et al.
Published: (2021-07-01)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
by: Bo Yu, et al.
Published: (2019-10-01)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
by: Jorge E. Cortes, et al.
Published: (2020-10-01)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
by: Daniil Zaytsev, et al.
Published: (2020-02-01)

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis
by: Qingyu Xu, et al.
Published: (2021-08-01)

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
by: Benoît Brethon, et al.
Published: (2021-02-01)

A rare case of fatal hepatic veno-occlusive disease and rupture of the spleen vein and artery after Gemtuzumab Ozogamicin (Mylotarg®) infusion Doença veno-oclusiva fatal por Gentuzumab Ozogamicin
by: Celso M. Massumoto, et al.
Published: (2004-01-01)

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin
by: Maurizio Cianfriglia
Published: (2013-06-01)

Targeting of CD34<sup>+</sup>CD38<sup>-</sup> cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
by: Jawad Mays, et al.
Published: (2012-09-01)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
by: Matteo Molica, et al.
Published: (2021-06-01)

Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia
by: Moo-Kon Song, et al.
Published: (2021-05-01)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
by: Alessandro Fiorentini, et al.
Published: (2020-01-01)

Novel Agents for Acute Myeloid Leukemia
by: Mario Luppi, et al.
Published: (2018-11-01)

Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
by: Christian M. Schürch
Published: (2018-05-01)

ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
by: saveria capria, et al.
Published: (2012-01-01)

ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
by: saveria capria, et al.
Published: (2012-11-01)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01)

Biphenotypic acute leukemia with t(15;17) lacking promyelocytic-retinoid acid receptor α rearrangement
by: Makoto Saito, et al.
Published: (2013-12-01)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
by: David I. Marks, et al.
Published: (2019-10-01)

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)
by: Maurizio Cianfriglia
Published: (2013-06-01)

Structural Characterization of the Aggregates of Gemtuzumab Ozogamicin
by: Qingping Jiang, et al.
Published: (2019-04-01)

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
by: Warren Fingrut, et al.
Published: (2021-12-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
by: Darshana Jani, et al.
Published: (2018-02-01)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019-04-01)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
by: Elena Tirrò, et al.
Published: (2019-02-01)

Recurrences of acute promyelocytic leukemia in children: experience with arsenic trioxide therapy and autologous hemopoietic cell transplantation
by: D D Baidildina, et al.
Published: (2010-07-01)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
by: Masaya Abe, et al.
Published: (2021-01-01)

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
by: Andrea Ghelli Luserna di Rorà, et al.
Published: (2020-09-01)

New Therapeutic Approaches for Acute Myeloid Leukaemia
by: Ruth M. Risueño, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_6pd3f27n4h3k95juf8gkl30ib6